HeartSciences (HSCS) Stock Price, News & Analysis

Company Overview

HeartSciences, Inc. (NASDAQ: HSCS) is a medical technology company focused on developing and commercializing innovative products for early detection of cardiovascular conditions. Its flagship offering, ECGScan, is a software-based electrocardiogram (ECG) acquisition and analysis platform that integrates artificial intelligence algorithms to enhance cardiac event detection. The company’s solutions are designed for use in primary care settings, emergency departments, urgent care centers and remote monitoring applications, providing clinicians with rapid and reliable diagnostic information to support patient management decisions.

Founded in the early 2000s, HeartSciences has pursued a strategy of combining proprietary digital signal processing with advanced machine learning to improve ECG interpretation. The company holds multiple FDA clearances for its ECGScan platform and related devices, and it continues to invest in research and development to broaden its product pipeline. In addition to on-site ECG acquisition systems, HeartSciences offers cloud-based services that enable healthcare providers to transmit patient ECGs securely for review, storage and analysis, facilitating telemedicine workflows and reducing time to diagnosis.

HeartSciences markets its products and services primarily in the United States, with distribution partnerships in Europe, Asia and Latin America. Its customer base includes hospitals, cardiology practices, urgent care clinics and telehealth providers seeking cost-effective and scalable cardiac screening solutions. The company’s commercial team works closely with clinical partners to validate performance in diverse patient populations and care settings, ensuring that its technologies meet evolving standards of care.

The executive leadership at HeartSciences brings together seasoned professionals from the medical device, diagnostic software and healthcare services industries. The team is led by CEO John R. Chatterton, whose background includes senior roles in cardiovascular diagnostic companies, alongside a board of directors with expertise in regulatory affairs, strategic partnerships and clinical research. Together, they are committed to advancing early detection of heart disease through accessible, data-driven technologies that support better patient outcomes.

Key Stats

• Today's Range: $3.71 to $5.72
• 50-Day Range: $3.26 to $5.73
• 52-Week Range: $2.36 to $6.47
• Volume: 627,715 shs
• Average Volume: 123,763 shs
• Market Capitalization: $4.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Buy

HeartSciences Stock Analysis - MarketRank™

HeartSciences scored higher than 49% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

HeartSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

HeartSciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for HeartSciences are expected to grow in the coming year, from ($10.01) to ($8.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of HeartSciences is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of HeartSciences is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

HeartSciences has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.63% of the float of HeartSciences has been sold short.

Short Interest Ratio / Days to Cover

HeartSciences has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HeartSciences has recently increased by 143.11%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HeartSciences does not currently pay a dividend.

Dividend Growth

HeartSciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

19.63% of the float of HeartSciences has been sold short.

Short Interest Ratio / Days to Cover

HeartSciences has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HeartSciences has recently increased by 143.11%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.94

News Sentiment

HeartSciences has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for HeartSciences this week, compared to 0 articles on an average week.

Search Interest

3 people have searched for HSCS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, HeartSciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.80% of the stock of HeartSciences is held by insiders.

Percentage Held by Institutions

Only 17.24% of the stock of HeartSciences is held by institutions.

HSCS Stock Analysis - Frequently Asked Questions

How have HSCS shares performed this year?

HeartSciences' stock was trading at $3.82 at the beginning of 2025. Since then, HSCS stock has increased by 8.9% and is now trading at $4.16.

How were HeartSciences' earnings last quarter?

HeartSciences Inc. (NASDAQ:HSCS) issued its earnings results on Thursday, March, 13th. The company reported ($2.57) earnings per share for the quarter, missing analysts' consensus estimates of ($2.53) by $0.04.

When did HeartSciences' stock split?

HeartSciences shares reverse split on the morning of Friday, May 17th 2024.The 1-100 reverse split was announced on Friday, May 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

When did HeartSciences IPO?

HeartSciences (HSCS) raised $9 million in an IPO on Wednesday, June 15th 2022. The company issued 1,800,000 shares at $4.50-$5.50 per share. The Benchmark Company acted as the underwriter for the IPO.

How do I buy shares of HeartSciences?

Shares of HSCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of HeartSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HeartSciences investors own include Meta Platforms (META), Cardio Diagnostics (CDIO), Invesco QQQ (QQQ), RH (RH), Exxon Mobil (XOM), Amarin (AMRN) and American Express (AXP).

Company Calendar

• Last Earnings: 3/13/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 4/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:HSCS
• CIK: 1468492
• Web: heartsciences.com
• Phone: 682-237-7781
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for HeartSciences: $13.00
• High Price Target: $14.00
• Low Price Target: $12.00
• Potential Upside/Downside: +222.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.61 million
• Net Margins: N/A
• Pretax Margin: -50,833.34%
• Return on Equity: -178.80%
• Return on Assets: -109.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.02
• Quick Ratio: 0.83

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.16 per share
• Price / Book: 0.36

Miscellaneous

• Outstanding Shares: 1,081,000
• Free Float: 1,062,000
• Market Cap: $4.36 million
• Optionable: Not Optionable
• Beta: 2.57